[Obesity and type 2 diabetes (Update 2023)].
Adipositas und Typ-2-Diabetes (Update 2023).
Body composition
Formula diets
Nutrition
Obesity
Type 2 diabetes
Journal
Wiener klinische Wochenschrift
ISSN: 1613-7671
Titre abrégé: Wien Klin Wochenschr
Pays: Austria
ID NLM: 21620870R
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
accepted:
28
02
2023
medline:
28
4
2023
pubmed:
27
4
2023
entrez:
26
4
2023
Statut:
ppublish
Résumé
The body mass index (BMI) is a very crude measure of body fatness in individuals. Even normal weight persons can have too much body fat in cases of a lack of muscle mass (sarcopenia), which is why additional measurements of waist circumference and body fatness, e.g. bioimpedance analysis (BIA), are recommended. Lifestyle management including nutrition modification and increase in physical activity are important measures for the prevention and treatment of diabetes. Regarding the treatment of type 2 diabetes, body weight is increasingly used as a secondary target parameter. The choice of anti-diabetic treatment and additional concomitant therapies is increasingly influenced by body weight. The importance of modern GLP‑1 agonists and dual GLP‑1 GIP agonists increases since these drugs target obesity and type 2 diabetes. Bariatric surgery is at present indicated with a BMI > 35 kg/m Der Body-Mass-Index (BMI) ist individuell betrachtet ein sehr grobes Maß für den Anteil des Körperfetts am Körpergewicht. Sogar Normalgewichtige können bei Muskelmangel zu viel Körperfett aufweisen (Sarkopenie), weswegen zusätzlich Messungen der Körperzusammensetzung (z. B. Bioimpedanzanalyse [BIA]) empfohlen werden. Lebensstilmanagement mit Ernährungsumstellung und Bewegung ist eine der wichtigsten Maßnahmen in der Diabetesprävention und -therapie. In der Therapie des Typ-2-Diabetes hat das Gewicht als sekundärer Zielparameter zunehmende Bedeutung erlangt. Auch die Wahl der antidiabetischen Therapie, aber auch der Begleittherapien nimmt immer mehr darauf Rücksicht. Die modernen GLP‑1 Analoga als auch der kombinierte GLP-1–GIP-Agonist Tirzepatid nehmen einen wichtigen Stellenwert in der gemeinsamen Behandlung von Adipositas und Diabetes mellitus Typ 2 ein. Die bariatrische Chirurgie ist derzeit bei an Diabetes mellitus Typ 2 erkrankten Menschen mit BMI > 35 kg/m
Autres résumés
Type: Publisher
(ger)
Der Body-Mass-Index (BMI) ist individuell betrachtet ein sehr grobes Maß für den Anteil des Körperfetts am Körpergewicht. Sogar Normalgewichtige können bei Muskelmangel zu viel Körperfett aufweisen (Sarkopenie), weswegen zusätzlich Messungen der Körperzusammensetzung (z. B. Bioimpedanzanalyse [BIA]) empfohlen werden. Lebensstilmanagement mit Ernährungsumstellung und Bewegung ist eine der wichtigsten Maßnahmen in der Diabetesprävention und -therapie. In der Therapie des Typ-2-Diabetes hat das Gewicht als sekundärer Zielparameter zunehmende Bedeutung erlangt. Auch die Wahl der antidiabetischen Therapie, aber auch der Begleittherapien nimmt immer mehr darauf Rücksicht. Die modernen GLP‑1 Analoga als auch der kombinierte GLP-1–GIP-Agonist Tirzepatid nehmen einen wichtigen Stellenwert in der gemeinsamen Behandlung von Adipositas und Diabetes mellitus Typ 2 ein. Die bariatrische Chirurgie ist derzeit bei an Diabetes mellitus Typ 2 erkrankten Menschen mit BMI > 35 kg/m
Identifiants
pubmed: 37101029
doi: 10.1007/s00508-023-02184-6
pii: 10.1007/s00508-023-02184-6
pmc: PMC10133053
doi:
Substances chimiques
Glucagon-Like Peptide 1
89750-14-1
Types de publication
English Abstract
Journal Article
Langues
ger
Sous-ensembles de citation
IM
Pagination
91-97Informations de copyright
© 2023. The Author(s).
Références
EUROSTAT. European heatlh interview survey. 2016.
Prospective Studies Collaboration, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373(9669):1083–96.
pmcid: 2662372
doi: 10.1016/S0140-6736(09)60318-4
Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world—a growing challenge. N Engl J Med. 2007;356(3):213–5.
pubmed: 17229948
doi: 10.1056/NEJMp068177
Oldridge NB, et al. Prevalence and outcomes of comorbid metabolic and cardiovascular conditions in middle- and older-age adults. J Clin Epidemiol. 2001;54(9):928–34.
pubmed: 11520653
doi: 10.1016/S0895-4356(01)00350-X
Fruhbeck G, et al. Obesity: the gateway to ill health—an EASO position statement on a rising public health, clinical and scientific challenge in Europe. Obes Facts. 2013;6(2):117–20.
pubmed: 23548858
pmcid: 5644725
doi: 10.1159/000350627
Finucane MM, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet. 2011;377(9765):557–67.
pubmed: 21295846
pmcid: 4472365
doi: 10.1016/S0140-6736(10)62037-5
Kelly T, et al. Global burden of obesity in 2005 and projections to 2030. Int J Obes. 2008;32(9):1431–7.
doi: 10.1038/ijo.2008.102
WHO. Obesity and overweight fact sheet no.311. 2016.
Gomez-Ambrosi J, et al. Body mass index classification misses subjects with increased cardiometabolic risk factors related to elevated adiposity. Int J Obes. 2012;36(2):286–94.
doi: 10.1038/ijo.2011.100
Cruz-Jentoft AJ, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people. Age Ageing. 2010;39(4):412–23.
pubmed: 20392703
pmcid: 2886201
doi: 10.1093/ageing/afq034
Delmonico MJ, et al. Alternative definitions of sarcopenia, lower extremity performance, and functional impairment with aging in older men and women. J Am Geriatr Soc. 2007;55(5):769–74.
pubmed: 17493199
doi: 10.1111/j.1532-5415.2007.01140.x
Goodpaster BH, et al. The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. J Gerontol A Biol Sci Med Sci. 2006;61(10):1059–64.
pubmed: 17077199
doi: 10.1093/gerona/61.10.1059
WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157–63.
doi: 10.1016/S0140-6736(03)15268-3
Tsigos C, et al. Management of obesity in adults: European clinical practice guidelines. Obes Facts. 2008;1(2):106–16.
pubmed: 20054170
pmcid: 6452117
doi: 10.1159/000126822
Yumuk V, et al. An EASO position statement on multidisciplinary obesity management in adults. Obes Facts. 2014;7(2):96–101.
pubmed: 24685592
pmcid: 5644787
doi: 10.1159/000362191
Morley JE, Anker SD, von Haehling S. Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology-update 2014. J Cachexia Sarcopenia Muscle. 2014;5(4):253–9.
pubmed: 25425503
pmcid: 4248415
doi: 10.1007/s13539-014-0161-y
Malmstrom TK, et al. SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes. J Cachexia Sarcopenia Muscle. 2016;7(1):28–36.
pubmed: 27066316
doi: 10.1002/jcsm.12048
Tsai SA, et al. Gender differences in weight-related attitudes and behaviors among overweight and obese adults in the United States. Am J Mens Health. 2016;10(5):389–98.
pubmed: 25595019
doi: 10.1177/1557988314567223
Grebitus C, Hartmann M, Reynolds N. Global obesity study on drivers for weight reduction strategies. Obes Facts. 2015;8(1):77–86.
pubmed: 25765165
pmcid: 5644806
doi: 10.1159/000373905
Yumuk V, et al. European guidelines for obesity management in adults. Obes Facts. 2015;8(6):402–24.
pubmed: 26641646
pmcid: 5644856
doi: 10.1159/000442721
Wycherley TP, et al. Long-term effects of a very low-carbohydrate weight loss diet on exercise capacity and tolerance in overweight and obese adults. J Am Coll Nutr. 2014;33(4):267–73.
pubmed: 24988413
doi: 10.1080/07315724.2014.911668
Otto M, et al. Handgrip strength as a predictor for post bariatric body composition. Obes Surg. 2014;24(12):2082–8.
pubmed: 24902652
doi: 10.1007/s11695-014-1299-6
Hainer V, Toplak H, Stich V. Fat or fit: what is more important? Diabetes Care. 2009;32(2):S392–7.
pubmed: 19875587
pmcid: 2811477
doi: 10.2337/dc09-S346
Cawthon PM, et al. Do muscle mass, muscle density, strength, and physical function similarly influence risk of hospitalization in older adults? J Am Geriatr Soc. 2009;57(8):1411–9.
pubmed: 19682143
pmcid: 3269169
doi: 10.1111/j.1532-5415.2009.02366.x
Larsen RN, et al. The effect of high-protein, low-carbohydrate diets in the treatment of type 2 diabetes: a 12 month randomised controlled trial. Diabetologia. 2011;54(4):731–40.
pubmed: 21246185
doi: 10.1007/s00125-010-2027-y
Shai I, et al. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med. 2008;359(3):229–41.
pubmed: 18635428
doi: 10.1056/NEJMoa0708681
Krebs JD, et al. The diabetes excess weight loss (DEWL) trial: a randomised controlled trial of high-protein versus high-carbohydrate diets over 2 years in type 2 diabetes. Diabetologia. 2012;55(4):905–14.
pubmed: 22286528
doi: 10.1007/s00125-012-2461-0
Esposito K, et al. Effects of a Mediterranean-style diet on the need for antihyperglycemic drug therapy in patients with newly diagnosed type 2 diabetes: a randomized trial. Ann Intern Med. 2009;151(5):306–14.
pubmed: 19721018
doi: 10.7326/0003-4819-151-5-200909010-00004
Dansinger ML, et al. Comparison of the Atkins, Ornish, weight watchers, and zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA. 2005;293(1):43–53.
pubmed: 15632335
doi: 10.1001/jama.293.1.43
Wadden TA, et al. One-year weight losses in the Look AHEAD study: factors associated with success. Obesity (Silver Spring). 2009;17(4):713–22.
pubmed: 19180071
pmcid: 2690396
doi: 10.1038/oby.2008.637
Halle M, et al. Meal replacement by formula diet reduces weight more than a lifestyle intervention alone in patients with overweight or obesity and accompanied cardiovascular risk factors-the ACOORH trial. Eur J Clin Nutr. 2021;75(4):661–9.
pubmed: 33128036
doi: 10.1038/s41430-020-00783-4
Leitner DR, et al. Obesity and type 2 diabetes: two diseases with a need for combined treatment strategies—EASO can lead the way. Obes Facts. 2017;10(5):483–92.
pubmed: 29020674
pmcid: 5741209
doi: 10.1159/000480525
Zidek W, et al. First-line antihypertensive treatment in patients with pre-diabetes: rationale, design and baseline results of the ADaPT investigation. Cardiovasc Diabetol. 2008;7:22.
pubmed: 18652658
pmcid: 2529270
doi: 10.1186/1475-2840-7-22
Lindstrom J, et al. The Finnish diabetes prevention study (DPS): lifestyle intervention and 3‑year results on diet and physical activity. Diabetes Care. 2003;26(12):3230–6.
pubmed: 14633807
doi: 10.2337/diacare.26.12.3230
Knowler WC, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403.
pubmed: 11832527
doi: 10.1056/NEJMoa012512
Lean ME, et al. Obesity, weight loss and prognosis in type 2 diabetes. Diabet Med. 1990;7(3):228–33.
pubmed: 2139394
doi: 10.1111/j.1464-5491.1990.tb01375.x
Williamson DF, et al. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care. 2000;23(10):1499–504.
pubmed: 11023143
doi: 10.2337/diacare.23.10.1499
Wing RR, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34(7):1481–6.
pubmed: 21593294
pmcid: 3120182
doi: 10.2337/dc10-2415
Look ARG, Wing RR. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med. 2010;170(17):1566–75.
Foster GD, et al. A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the Sleep AHEAD study. Arch Intern Med. 2009;169(17):1619–26.
pubmed: 19786682
pmcid: 2879275
doi: 10.1001/archinternmed.2009.266
Rubin RR, et al. Impact of intensive lifestyle intervention on depression and health-related quality of life in type 2 diabetes: the Look AHEAD Trial. Diabetes Care. 2014;37(6):1544–53.
pubmed: 24855155
doi: 10.2337/dc13-1928
Lean ME, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018;391(10120):541–51.
pubmed: 29221645
doi: 10.1016/S0140-6736(17)33102-1
Toplak H, et al. 2014 EASO position statement on the use of anti-obesity drugs. Obes Facts. 2015;8(3):166–74.
pubmed: 25968960
pmcid: 5644876
doi: 10.1159/000430801
Berne C, Orlistat Swedish Type 2 diabetes Study Group. A randomized study of orlistat in combination with a weight management programme in obese patients with type 2 diabetes treated with metformin. Diabet Med. 2005;22(5):612–8.
pubmed: 15842517
doi: 10.1111/j.1464-5491.2004.01474.x
Hollander P, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36(12):4022–9.
pubmed: 24144653
pmcid: 3836105
doi: 10.2337/dc13-0234
Davies MJ, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA. 2015;314(7):687–99.
pubmed: 26284720
doi: 10.1001/jama.2015.9676
Kelly AS, et al. A randomized, controlled trial of liraglutide for adolescents with obesity. N Engl J Med. 2020;382(22):2117–28.
pubmed: 32233338
doi: 10.1056/NEJMoa1916038
Davies M, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971–84.
pubmed: 33667417
doi: 10.1016/S0140-6736(21)00213-0
Weghuber D, et al. Once-weekly semaglutide in adolescents with obesity. N Engl J Med. 2022;387(24):2245–57.
pubmed: 36322838
pmcid: 9997064
doi: 10.1056/NEJMoa2208601
Rosenstock J, et al. Efficacy and safety of a novel dual GIP and GLP‑1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143–55.
pubmed: 34186022
doi: 10.1016/S0140-6736(21)01324-6
Frias JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503–15.
pubmed: 34170647
doi: 10.1056/NEJMoa2107519
Dahl D, et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS‑5 randomized clinical trial. JAMA. 2022;327(6):534–45.
pubmed: 35133415
pmcid: 8826179
doi: 10.1001/jama.2022.0078
Sjostrom L, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351(26):2683–93.
pubmed: 15616203
doi: 10.1056/NEJMoa035622
Pories WJ. Bariatric surgery: risks and rewards. J Clin Endocrinol Metab. 2008;93(11):S89–96.
pubmed: 18987275
pmcid: 2729256
doi: 10.1210/jc.2008-1641
Sjostrom L. Review of the key results from the Swedish obese subjects (SOS) trial—a prospective controlled intervention study of bariatric surgery. J Intern Med. 2013;273(3):219–34.
pubmed: 23163728
doi: 10.1111/joim.12012
Neovius M, et al. Health care use during 20 years following bariatric surgery. JAMA. 2012;308(11):1132–41.
pubmed: 22990272
doi: 10.1001/2012.jama.11792
Thibault R, et al. Twelve key nutritional issues in bariatric surgery. Clin Nutr. 2016;35(1):12–7.
pubmed: 25779332
doi: 10.1016/j.clnu.2015.02.012
Busetto L, et al. Practical recommendations of the obesity management task force of the European association for the study of obesity for the post-bariatric surgery medical management. Obes Facts. 2017;10(6):597–632.
pubmed: 29207379
pmcid: 5836195
doi: 10.1159/000481825
Busetto L, et al. Obesity management task force of the European association for the study of obesity released „practical recommendations for the post-bariatric surgery medical management“. Obes Surg. 2018;28(7):2117–21.
pubmed: 29725979
doi: 10.1007/s11695-018-3283-z
Sjoholm K, et al. Incidence and remission of type 2 diabetes in relation to degree of obesity at baseline and 2 year weight change: the Swedish obese subjects (SOS) study. Diabetologia. 2015;58(7):1448–53.
pubmed: 25924987
doi: 10.1007/s00125-015-3591-y
Rubino F, et al. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care. 2016;39(6):861–77.
pubmed: 27222544
doi: 10.2337/dc16-0236
Schauer PR, Nor Hanipah Z, Rubino F. Metabolic surgery for treating type 2 diabetes mellitus: now supported by the world’s leading diabetes organizations. Cleve Clin J Med. 2017;84(7):S47–S56.
pubmed: 28708482
doi: 10.3949/ccjm.84.s1.06
Buchwald H, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122(3):248–256.e5.
pubmed: 19272486
doi: 10.1016/j.amjmed.2008.09.041
Buchwald H, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292(14):1724–37.
pubmed: 15479938
doi: 10.1001/jama.292.14.1724
Schauer PR, et al. Bariatric surgery versus intensive medical therapy for diabetes—5-year outcomes. N Engl J Med. 2017;376(7):641–51.
pubmed: 28199805
pmcid: 5451258
doi: 10.1056/NEJMoa1600869